A device for treating retinal aging diseases by acting transdermally on the upper eyelid

Abstract

This invention relates to the field of ophthalmic medical device technology, specifically to a device for treating retinal aging diseases by acting on the transdermal surface of the upper eyelid. The device includes a lens frame, a lamp head, and a control assembly. The lens frame includes a frame and temples connected by a connector. At least one slot for mounting the lamp head is provided at the top of the frame. First electrode plates are disposed on both sides of the interior of the slot. These first electrode plates are electrically connected to the control assembly via a power transmission line. The control assembly controls the lamp head to output light at a preset frequency. In practical applications, the lens frame facilitates wearing the device, the detachable connection between the lamp head and the slot facilitates replacement of the consumable lamp head, and the control assembly controls the lamp head to emit light at a preset frequency that acts on the transdermal surface of the upper eyelid, thus effectively treating retinal aging diseases.

Description

Technical Field

[0001] This invention relates to the field of ophthalmic medical device technology, specifically to a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid. Background Technology

[0002] Current technologies for treating retinal aging diseases (such as age-related macular degeneration and diabetic lesions) typically employ drug therapy. However, drug therapy is often ineffective and has certain side effects.

[0003] Currently, some phototherapy devices have emerged for retinal treatment. For example, patent publication number CN215136060U discloses a phototherapy device for retinal treatment, which specifically uses a head and eye fixation device to solve the problem in existing technologies where patients tend to flinch when facing the phototherapy irradiation, affecting the treatment effect. However, such phototherapy devices for retinal treatment still have the following problems in actual use:

[0004] 1. The light emitted by this type of phototherapy device is high-brightness and high-energy light. During the treatment process, only a doctor can operate the phototherapy device for treatment, and it cannot be used by the patient alone.

[0005] 2. Because the patient's head needs to be fixed and eyes need to be open during treatment using this type of phototherapy device, the patient experiences significant psychological stress during the treatment process, and cannot stop the treatment immediately if discomfort occurs.

[0006] 3. The light emitted by this type of phototherapy device acts directly on the patient's eyeball, and the amount of light entering the eyeball cannot be accurately controlled, resulting in poor treatment effect;

[0007] 4. These phototherapy devices have a complex and bulky structure, making them unsuitable for personal use and costly.

[0008] Therefore, there is an urgent need for a device that acts on the transdermal surface of the upper eyelid to treat retinal aging diseases in order to solve the above problems. Summary of the Invention

[0009] To address the problems existing in the above-mentioned background art, the present invention provides a device for treating retinal aging diseases by acting transdermally on the upper eyelid.

[0010] To achieve the above objectives, the present invention provides a device for treating retinal aging diseases by acting on the transdermal surface of the upper eyelid, the device comprising a lens frame, a lamp head, and a control assembly;

[0011] The eyeglass frame includes a frame and temples, which are connected by a connector. The top of the frame has at least one slot for mounting the lamp head. The slot has a first electrode plate on both sides. The first electrode plate is electrically connected to the control component via a power transmission line. The control component is used to control the lamp head to output light at a preset frequency.

[0012] Preferably, the lamp head includes a lamp box and a pin that matches the slot. A second electrode plate is provided on both sides of the slot end of the pin. A lamp groove is provided on the pin. A spring is provided at the bottom of the lamp groove. The lamp box is installed in the lamp groove by the spring. An LED bead is provided inside the lamp box. A light guide port is provided on the lamp box. The second electrode plate is electrically connected to the LED bead.

[0013] Preferably, the angle α between the light guide port and the horizontal plane is 16-20°.

[0014] Preferably, the light box contact surface of the light trough is a smooth surface.

[0015] Preferably, the control component includes a main control board and a power supply for powering the main control board. The main control board integrates a lamp head driver unit, and the main control board controls the lamp head to output yellow light of a preset frequency, which is 35-45Hz, through the lamp head driver unit.

[0016] Preferably, the lamp head driving unit includes a metal-oxide-semiconductor field-effect transistor (MOSFET), which is used to control the lamp head to turn on and off at a preset frequency according to the high and low level signals of the main control board.

[0017] Preferably, the main control board also integrates a current controller, which is used to adjust the brightness of the lamp head, wherein the brightness adjustment range of the lamp head is 3.0-35.0 mW / cm². 2 .

[0018] Preferably, the bottom of the slot is also connected to a first wiring groove, and the inside of the temple is provided with a second wiring groove. The end of the second wiring groove away from the frame is provided with a socket, and the first electrode is connected to the socket through a connecting wire provided in the first wiring groove and the second wiring groove.

[0019] Preferably, the first electrode sheet is an electrode spring.

[0020] Preferably, the two ends of the power transmission line are detachably connected to the socket and the control component, respectively.

[0021] According to the above technical solution, this device for treating retinal aging diseases by acting on the transdermal surface of the upper eyelid can be conveniently worn for treatment by setting the lens frame. The detachable connection between the lamp head and the slot facilitates the replacement of the easily consumable lamp head and allows for accurate control of the light coverage. The control component controls the lamp head to emit light of a preset frequency that acts on the transdermal surface of the upper eyelid, thus effectively treating retinal aging diseases. It has the advantages of good eye-treatment effect, simple structure, easy operation, individual use by the patient, no need for the patient to look directly at the light source, and low cost.

[0022] Meanwhile, the light box is equipped with a light guide port, and the angle α between the light guide port and the horizontal plane is 16-20°, which effectively controls the light coverage range, limiting it to the upper eyelid transdermis. This allows for accurate control of the amount of light entering the eyeball, unlike existing devices that directly act on the entire eyeball. Furthermore, patients can open their eyes at any time during treatment to stop the procedure, resulting in better treatment comfort. The control component includes a main control board and a power supply for the main control board. The main control board integrates a lamp head driver unit, which controls the lamp head to output yellow light at a preset frequency of 35-45Hz. The main control board also integrates a current controller for adjusting the lamp head's brightness intensity, which is adjustable within a range of 3.0-35.0 mW / cm². 2 This is intended to enable personalized treatment and improve treatment outcomes. Attached Figure Description

[0023] Figure 1 This is a schematic diagram of a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid;

[0024] Figure 2 This is a first-view structural diagram of the lens frame of a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid;

[0025] Figure 3 This is a second-view structural diagram of the lens frame of a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid;

[0026] Figure 4 This is a schematic diagram of the lamp head of a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid;

[0027] Figure 5 This is a schematic diagram of the control component of a treatment device for retinal aging diseases that acts on the transdermal surface of the upper eyelid;

[0028] Figure 6This is a first-view structural schematic diagram of the control component of a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid;

[0029] Figure 7 This is a diagram illustrating the specific application of a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid;

[0030] Figure 8 This is another specific application diagram of a device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid.

[0031] Explanation of reference numerals in the attached figures

[0032] Eyeglass frame 1; Eyeglass frame 101; Connector 102; Temple 103; Slot 104; First electrode plate 105;

[0033] Socket 106;

[0034] Lamp holder 2; pin 201; lamp box 202; second electrode plate 203; lamp trough 204; spring 205;

[0035] LED chip 206; Light guide port 207;

[0036] Control component 3; switch button 301; brightness adjustment mode button 302; working mode button 303;

[0037] Start and pause buttons 304; connector 305; power indicator light 306;

[0038] Power transmission line 4. Detailed Implementation

[0039] The specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings. It should be understood that the specific embodiments described herein are for illustration and explanation only and are not intended to limit the scope of the present invention.

[0040] In the description of this application, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating relative importance or implying the number of indicated technical features. Therefore, unless otherwise stated, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature; "multiple" means two or more. The term "comprising" and any variations thereof mean a non-exclusive inclusion, the possibility of the presence or addition of one or more other features, units, components, and / or combinations thereof.

[0041] Furthermore, unless otherwise explicitly specified and limited, the terms "installation," "connection," and "linking" should be interpreted broadly. For example, they can refer to fixed connections, detachable connections, or integral connections; they can refer to mechanical connections or electrical connections; they can refer to direct connections or indirect connections through an intermediate medium, or internal connections between two components. Those skilled in the art can understand the specific meaning of the above terms in this application based on the specific circumstances.

[0042] This invention provides a device for treating retinal aging diseases by acting transdermally on the upper eyelid, such as... Figure 1-8 As shown, the device for treating retinal aging diseases by transdermal application to the upper eyelid includes a lens frame 1, a lamp head 2, and a control assembly 3.

[0043] The eyeglass frame 1 includes a frame 101 and temples 103, which are connected by a connector 102. The top of the frame 101 has at least one slot 104 for mounting the lamp head 2. First electrode plates 105 are provided on both sides of the interior of each slot 104. The first electrode plates 105 are electrically connected to the control component 3 via a power transmission line 4. The control component 3 controls the lamp head 2 to output light at a preset frequency. Preferably, two slots 104 are provided.

[0044] In one specific embodiment, a first wiring groove is connected to the bottom of the slot 104, and a second wiring groove is provided inside the temple 103. A socket 106 is provided at the end of the second wiring groove away from the frame. The first electrode 105 is connected to the socket 106 via connecting wires disposed in the first and second wiring grooves. Thus, the power transmission line 4 can be connected to the first electrode 105 by connecting to the socket 106. In a more specific embodiment, the first electrode 105 is an electrode spring, allowing the lamp head 2 to be adjusted to the depth of insertion into the slot 104 according to the actual situation of different patients. In another more specific embodiment, both ends of the power transmission line 4 are detachably connected to the socket 106 and the control component 3, respectively. The power transmission line 4 is used for power supply and transmission of control signals.

[0045] According to the above technical solution, based on this device for treating retinal aging diseases through transdermal application of the upper eyelid, in practical applications, the frame 1 allows people to easily wear the device for treatment. The detachable connection between the lamp head 2 and the slot 104 facilitates the replacement of the consumable lamp head and accurately controls the light coverage. The control component 3 controls the lamp head 2 to emit light of a preset frequency that acts on the transdermal application of the upper eyelid, thus effectively treating retinal aging diseases. It has the advantages of good treatment effect in the eye, simple structure, easy operation, individual use by the patient, no need for the patient to look directly at the light source, and low cost.

[0046] In the retinal aging disease treatment device acting on the transdermal upper eyelid described in this invention, the lamp head 2 includes a lamp housing 202 and a pin 201 matched with the slot 104. Second electrode plates 203 are provided on both sides of the slot end of the pin 201. A lamp groove 204 is provided on the pin 201, and a spring 205 is provided at the bottom of the lamp groove 204. The lamp housing 202 is installed in the lamp groove 204 via the spring 205. An LED bead 206 is disposed inside the lamp housing 202, and a light guide port 207 is provided on the lamp housing 202. The second electrode plates 203 are electrically connected to the LED bead 206. In specific applications, the lamp head 2 is installed in the slot 104 via the pin 201. Preferably, the depth of the pin 201 inserted into the slot 104 is adjusted according to the actual situation of different patients, so that the light emitted by the LED bead 206 of the lamp head 2 covers only the transdermal upper eyelid through the light guide port 207. Specifically, as shown below... Figure 7-8 Install and use as shown.

[0047] Furthermore, in a preferred embodiment, such as Figure 4 As shown, the angle α between the light guide 207 and the horizontal plane is 16-20°. Most preferably, the angle α between the light guide 207 and the horizontal plane is 18°, so that in practical applications, the light emitted by the LED bead 206 can be transdermally applied to the patient's upper eyelid via the light guide 207, and the patient can open their eyes at any time to stop treatment if discomfort occurs. Wherein, as Figure 7 As shown, the design principle of the light guide 207 is that the upper eyelid acts as a natural filter, capable of filtering out short-wavelength light while retaining red and higher wavelength light. This light then illuminates the eye through the upper eyelid. Specifically, when the LED bead 206 emits yellow light, the patient can see red light. Furthermore, as... Figure 8As shown, when a patient feels uncomfortable and opens their eyes, the rolled-up upper eyelid thickens, reducing the amount of light penetrating the upper eyelid, and the upper eyelid cannot guide light to the eyeball. At this time, the light cannot reach the pupil, thus preventing light from directly shining into the eyes, thereby relieving the patient of any psychological stress.

[0048] Furthermore, in another preferred embodiment, such as Figure 4 As shown, the contact surface of the lamp box of the lamp slot 204 is a smooth surface, so that the lamp box 202 can better fit the patient's supraorbital skin under the action of the spring 205.

[0049] In the retinal aging disease treatment device acting on the transdermal upper eyelid described in this invention, the control component 3 includes a main control board and a power supply for powering the main control board. The main control board integrates a lamp head driver unit, which controls the lamp head 2 to output yellow light at a preset frequency of 35-45Hz. In a specific embodiment, the lamp head driver unit includes a metal-oxide-semiconductor field-effect transistor (MOSFET), which controls the lamp head 2 to turn on and off at a preset frequency based on high and low level signals from the main control board. Specifically, in a preferred embodiment, the main control board controls the MOSFET to switch on and off at a frequency of 40Hz via high and low level signals, thereby controlling the lamp head 2 to turn on and off at a frequency of 40Hz. In a more preferred embodiment, the main control board also integrates a current controller, which adjusts the light intensity of the lamp head 2, wherein the adjustment range of the light intensity of the lamp head 2 is 3.0-35.0 mW / cm². 2 In practical applications, the luminous intensity of the lamp head 2 is preferably 16.8 ± 0.4 mW / cm² under default conditions. 2 This is used to quickly adjust the light intensity to suit different patients.

[0050] The determination of the light intensity of the lamp head 2 will be further explained based on specific experimental data.

[0051] Experimental Method: Due to variations in eyelid thickness among individuals, the light intensity needed to be optimized for each patient. The minimum light intensity was defined as the intensity at which red light was initially perceived. The maximum light intensity was defined as the intensity at which the red light began to transition to yellow light, achieved by gradually increasing the brightness from the minimum. The optimized light intensity was the midpoint between the minimum and maximum light intensities, measured from the initial perception of red light to the point where the light began to turn yellow. The light emitted by lamp 2 was yellow light. At the minimum intensity, the yellow light penetrated the upper eyelid, and the patient perceived the light as red. At the maximum intensity, the yellow light penetrated the upper eyelid, and the patient perceived the light as yellow.

[0052] The experiment included 14 elderly participants aged 50 and above, regardless of gender, with a mean age of 66.4 ± 11.3 years. Each participant first received optimized light intensity illumination, rested for 2 minutes, then received optimized light intensity illumination for 3 minutes, rested for 2 minutes, received maximum light intensity illumination for 5 seconds, and finally opened their eyes under maximum light intensity. Patients rated their comfort / discomfort level as follows: -3 "very uncomfortable", -2 "uncomfortable", -1 "slightly uncomfortable", 0 "neither uncomfortable nor uncomfortable", 1 "slightly comfortable", 2 "comfortable", and 3 "very comfortable".

[0053] Experimental Results: After 3 minutes of optimized light intensity irradiation, 11 out of 14 participants scored "0", 3 scored "1", and no participants scored any other scores. At the highest light intensity for 5 seconds, 7 out of 14 participants scored "0", 7 scored "-1", and no participants scored any other scores. With their eyes open at the highest light intensity, none of the 14 participants experienced any light penetration into their pupils, and none experienced glare. The average minimum light intensity was determined to be 3.6 ± 0.3 mW / cm². 2 The average maximum luminous intensity is 29.9 ± 0.5 mW / cm². 2 The average optimized light intensity was 16.8 ± 0.4 mW / cm². 2 .

[0054] In this invention, in more specific embodiments, such as Figure 5-6 As shown, the main control board is an embedded main control board. The main control board is equipped with a power switch 301, a brightness adjustment mode button 302, a working mode button 303, and start and pause buttons 304. The power switch 301 controls the on / off operation of the transdermal retinal aging disease treatment device acting on the upper eyelid. The brightness adjustment mode button 302, i.e., the "0Hz 3min" mode, is used by doctors to adjust the light intensity of the lamp head 2 to the optimal value according to different patients. The adjustable range of the light intensity is 3.0-35.0 mW / cm². 2In actual use, after the doctor adjusts the brightness of the lamp head 2 according to the patient's condition, the patient can use it independently. The working mode button 303, i.e., the "40Hz 30min" mode, is used to treat retinal aging diseases by acting transdermally on the patient's upper eyelid. The start and pause buttons 304 are used to interrupt or continue the treatment process during use. In a more specific embodiment, the main control board is also equipped with a connection port 305 and a power indicator light 306. The connection port 305 is used to charge the power supply and control the lamp head 2 to work in a preset mode via the power transmission line 4. More specifically, the connection port 305 is a Type-C interface, which can also be connected to a computer for adjusting the brightness of the lamp head 2 via the computer in "0Hz 3min" mode to meet the needs of different patients. Alternatively, the brightness adjustment mode button 302 can be designed as a knob, allowing adjustment of the brightness of the lamp head 2 by rotation. The power indicator light 306 is used to display the power level.

[0055] According to a first embodiment of the present invention, the device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid includes a lens frame 1, a lamp head 2, and a control component 3.

[0056] The eyeglass frame 1 includes a frame 101 and temples 103, which are connected by a connector 102. The top of the frame 101 has at least one slot 104 for mounting the lamp head 2. The inside of the slot 104 has two sides provided with first electrode plates 105. The first electrode plates 105 are electrically connected to the control component 3 through a power transmission line 4. The control component 3 is used to control the lamp head 2 to output light of a preset frequency.

[0057] Specifically, the bottom of the slot 104 is connected to a first wiring groove, and the inside of the temple 103 is provided with a second wiring groove. A socket 106 is provided at the end of the second wiring groove away from the frame. The first electrode piece 105 is connected to the socket 106 via connecting wires disposed in the first and second wiring grooves. The first electrode piece 105 is an electrode spring. Both ends of the power transmission line 4 are detachably connected to the socket 106 and the control component 3, respectively.

[0058] The lamp holder 2 includes a lamp housing 202 and a pin 201 that matches the slot 104. Second electrode plates 203 are provided on both sides of the slot end of the pin 201. A lamp groove 204 is provided on the pin 201, and a spring 205 is provided at the bottom of the lamp groove 204. The lamp housing 202 is mounted in the lamp groove 204 via the spring 205. An LED bead 206 is disposed inside the lamp housing 202. A light guide port 207 is provided on the lamp housing 202. The second electrode plates 203 are electrically connected to the LED bead 206. The angle α between the light guide port 207 and the horizontal plane is 16-20°. The lamp housing contact surface of the lamp groove 204 is a smooth surface.

[0059] According to a second embodiment of the present invention, the device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid includes a lens frame 1, a lamp head 2, and a control component 3.

[0060] The eyeglass frame 1 includes a frame 101 and temples 103, which are connected by a connector 102. The top of the frame 101 has at least one slot 104 for mounting the lamp head 2. The inside of the slot 104 has two sides provided with first electrode plates 105. The first electrode plates 105 are electrically connected to the control component 3 through a power transmission line 4. The control component 3 is used to control the lamp head 2 to output light of a preset frequency.

[0061] Specifically, the bottom of the slot 104 is connected to a first wiring groove, and the inside of the temple 103 is provided with a second wiring groove. A socket 106 is provided at the end of the second wiring groove away from the frame. The first electrode piece 105 is connected to the socket 106 via connecting wires disposed in the first and second wiring grooves. The first electrode piece 105 is an electrode spring. Both ends of the power transmission line 4 are detachably connected to the socket 106 and the control component 3, respectively.

[0062] The lamp holder 2 includes a lamp housing 202 and a pin 201 that matches the slot 104. Second electrode plates 203 are provided on both sides of the slot end of the pin 201. A lamp groove 204 is provided on the pin 201, and a spring 205 is provided at the bottom of the lamp groove 204. The lamp housing 202 is mounted in the lamp groove 204 via the spring 205. An LED bead 206 is disposed inside the lamp housing 202. A light guide port 207 is provided on the lamp housing 202. The second electrode plates 203 are electrically connected to the LED bead 206. The angle α between the light guide port 207 and the horizontal plane is 16-20°. The lamp housing contact surface of the lamp groove 204 is a smooth surface.

[0063] The control component 3 includes a main control board and a power supply for powering the main control board. The main control board integrates a lamp head driver unit, which controls the lamp head 2 to output yellow light at a preset frequency of 35-45Hz. The lamp head driver unit includes a metal-oxide-semiconductor field-effect transistor (MOSFET), which controls the lamp head 2 to turn on and off at the preset frequency based on high and low level signals from the main control board. The main control board also integrates a current controller, which adjusts the light intensity of the lamp head 2 within a range of 3.0-35.0 mW / cm². 2 .

[0064] The present invention will be described in detail below through embodiments, but the scope of protection of the present invention is not limited thereto.

[0065] Example 1

[0066] like Figure 1-8 As shown, the retinal aging disease treatment device that acts on the transdermal surface of the upper eyelid described in this invention is used for the treatment of age-related macular degeneration. Specifically, the retinal aging disease treatment device that acts on the transdermal surface of the upper eyelid includes a mirror frame 1, a lamp head 2, and a control component 3.

[0067] The eyeglass frame 1 includes a frame 101 and temples 103, which are connected by a connector 102. The top of the frame 101 has two slots 104 for mounting the lamp head 2. The inside of each slot 104 has a first electrode plate 105 on both sides. The first electrode plate 105 is electrically connected to the control component 3 through a power transmission line 4. The control component 3 is used to control the lamp head 2 to output light of a preset frequency.

[0068] Specifically, the bottom of the slot 104 is connected to a first wiring groove, and the inside of the temple 103 is provided with a second wiring groove. A socket 106 is provided at the end of the second wiring groove away from the frame. The first electrode piece 105 is connected to the socket 106 via connecting wires disposed in the first and second wiring grooves. The first electrode piece 105 is an electrode spring. Both ends of the power transmission line 4 are detachably connected to the socket 106 and the control component 3, respectively.

[0069] The lamp holder 2 includes a lamp housing 202 and a pin 201 that matches the slot 104. Second electrode plates 203 are provided on both sides of the slot end of the pin 201. A lamp groove 204 is provided on the pin 201, and a spring 205 is provided at the bottom of the lamp groove 204. The lamp housing 202 is mounted in the lamp groove 204 via the spring 205. An LED bead 206 is disposed inside the lamp housing 202. A light guide port 207 is provided on the lamp housing 202. The second electrode plates 203 are electrically connected to the LED bead 206. The angle α between the light guide port 207 and the horizontal plane is 18°. The lamp housing contact surface of the lamp groove 204 is a smooth surface.

[0070] In practical application, the device for treating retinal aging diseases that acts on the transdermal surface of the upper eyelid is first connected and set up. Then, the patient wears the eyeglass frame 1. According to the patient's eye characteristics, the doctor inserts the pin 201 of the lamp head 2 into the slot 104 to a certain depth, so that the light emitted by the lamp bead 206 covers the transdermal surface of the upper eyelid through the light guide port 207. Then, the patient closes his / her eyes, and the control component 3 controls the lamp head 2 to output light of a preset frequency to treat the patient's retinal aging disease.

[0071] Testing revealed that the retinal aging disease treatment device for transdermal upper eyelids described in this invention, by adjusting the depth of the pin 201 of the lamp head 2 inserted into the slot 104 according to different patients, can effectively improve the applicability of the device. Furthermore, the lamp head 2 can be replaced periodically to ensure treatment effectiveness. With the light guide port 207 and the horizontal plane forming an angle α of 18°, the treatment effect can be improved by accurately controlling the amount of light entering the eyeball. Moreover, patients can easily open their eyes to stop treatment if discomfort occurs during the process, without any psychological pressure, resulting in good treatment comfort. Additionally, patients do not need to look directly at the light source during treatment, effectively avoiding damage to the patient's eyeballs caused by high-brightness, high-energy light due to malfunction of the phototherapy device or human error.

[0072] Example 2

[0073] The retinal aging disease treatment device that acts on the transdermal surface of the upper eyelid as described in Example 1 differs in that it specifically further includes:

[0074] The control component 3 includes a main control board and a power supply for powering the main control board. The main control board integrates a lamp head driver unit, which controls the lamp head 2 to output yellow light at a preset frequency of 40Hz. The lamp head driver unit includes a metal-oxide-semiconductor field-effect transistor (MOSFET), which controls the lamp head 2 to turn on and off at the preset frequency based on high and low level signals from the main control board. The main control board also integrates a current controller, which adjusts the light intensity of the lamp head 2 within a range of 3.0-35.0 mW / cm². 2 .

[0075] In practical application, the aforementioned retinal aging disease treatment device acting on the transdermal surface of the upper eyelid is first connected and set up. Then, the patient wears the eyeglass frame 1. Based on the patient's eye characteristics, the doctor inserts the pin 201 of the lamp head 2 into the slot 104 to a certain depth, so that the light emitted by the lamp beads 206 covers the transdermal surface of the upper eyelid through the light guide port 207. Then, the patient closes their eyes, and the light intensity of the lamp head 2 is adjusted to 16.8 mW / cm² using the current controller. 2 Then, the main control board controls the metal-oxide-semiconductor field-effect transistor to close and open at a frequency of 40Hz via the high and low level signals, thereby controlling the lamp head 2 to emit light at a frequency of 40Hz with a brightness of 16.8mW / cm². 2 Yellow light is used to treat age-related retinal diseases in patients.

[0076] Testing revealed that the retinal aging disease treatment device for transdermal upper eyelids described in this invention, by adjusting the depth of the pin 201 of the lamp head 2 inserted into the slot 104 according to different patients, effectively improves the applicability of the device. Furthermore, the lamp head 2 can be replaced periodically, ensuring treatment effectiveness. The 18° angle α between the light guide port 207 and the horizontal plane not only allows for precise control of the amount of light entering the eye, improving treatment effectiveness, but also allows patients to open their eyes at any time to stop treatment if discomfort occurs, without any psychological pressure, resulting in good treatment comfort. Simultaneously, patients do not need to look directly at the light source during treatment, effectively avoiding damage to the patient's eyeballs caused by high-brightness, high-energy light due to phototherapy device malfunction or human error. Further, the light intensity of the lamp head 2 can be adjusted to 16.8 mW / cm² using the current controller. 2 Then, the main control board controls the metal-oxide-semiconductor field-effect transistor to close and open at a frequency of 40Hz via the high and low level signals, thereby controlling the lamp head 2 to emit light at a frequency of 40Hz with a brightness of 16.8mW / cm². 2Yellow light can further improve the treatment effect, and patients do not experience significant discomfort during the treatment process, showing good application prospects.

[0077] The present invention provides a device for treating retinal aging diseases via transdermal application to the upper eyelid. This device can accurately control the amount of light entering the eyeball and emits light at a frequency of 40Hz with an intensity of 16.8 mW / cm². 2 The yellow light acts on the transdermal layer of the upper eyelid, significantly improving the treatment effect of retinal aging diseases.

[0078] The preferred embodiments of the present invention have been described in detail above with reference to the accompanying drawings; however, the present invention is not limited thereto. Within the scope of the inventive concept, various simple modifications can be made to the technical solutions of the present invention. To avoid unnecessary repetition, the present invention will not describe the various possible combinations separately. However, these simple modifications and combinations should also be considered as the content disclosed in the present invention and are all within the protection scope of the present invention.

Claims

1. A device for treating retinal aging disease by transdermal action on the upper eyelid, characterized in that, The device for treating retinal aging diseases through the upper eyelid transdermally comprises a mirror frame (1), a lamp head (2) and a control assembly (3); The mirror frame (1) comprises a mirror frame (101) and a mirror leg (103), and the mirror frame (101) and the mirror leg (103) are connected through a connecting piece (102); the top of the mirror frame (101) is provided with at least one insertion slot (104) for mounting the lamp head (2); both sides of the inside of the insertion slot (104) are provided with first electrode sheets (105); the first electrode sheets (105) are electrically connected with the control assembly (3) through a power transmission line (4); and the control assembly (3) is used for controlling the lamp head (2) to output light of a preset frequency. The lamp head (2) comprises a lamp box (202) and a plug (201) matched with the insertion slot (104); both sides of the insertion slot end of the plug (201) are provided with second electrode sheets (203); the plug (201) is provided with a lamp groove (204); the bottom of the lamp groove (204) is provided with a spring (205); the lamp box (202) is mounted in the lamp groove (204) through the spring (205); the inside of the lamp box (202) is provided with a lamp bead (206); the lamp box (202) is provided with a light guide port (207); and the second electrode sheets (203) are electrically connected with the lamp bead (206). The included angle a between the light guide port (207) and the horizontal plane is 16-20°. The control assembly (3) comprises a main control board and a power supply for supplying power to the main control board; the main control board is integrated with a lamp head driving unit; the main control board controls the lamp head (2) to output yellow light of a preset frequency through the lamp head driving unit; and the preset frequency is 35-45 Hz.

2. The retinal aging disease treatment device for transdermal action on the upper eyelid according to claim 1, characterized by, The lamp box contact surface of the lamp groove (204) is a smooth surface.

3. The retinal aging disease treatment device for transdermal action on the upper eyelid according to claim 1, characterized by, The lamp head driving unit comprises a metal-oxide-semiconductor field effect transistor (MOSFET) for controlling the lamp head (2) to brighten and dim at a preset frequency according to the high and low level signals of the main control board.

4. The retinal aging disease treatment device for transdermal action on the upper eyelid according to claim 1 or 3, characterized by, The main control board is also integrated with a current controller, which is used to adjust the light intensity of the lamp holder (2), wherein the adjustment range of the light intensity of the lamp holder (2) is 3.0-35.0mW / cm 2 .

5. The retinal aging disease treatment device for transdermal action on the upper eyelid according to claim 1, characterized by, The bottom of the insertion slot (104) is further connected with a first wiring slot; the inside of the mirror leg (103) is provided with a second wiring slot; one end of the second wiring slot away from the mirror frame is provided with a jack (106); and the first electrode sheets (105) are connected with the jack (106) through connecting lines arranged in the first wiring slot and the second wiring slot.

6. The retinal age-related disease treatment device for transdermal action on the upper eyelid according to claim 5, characterized by The first electrode sheets (105) are electrode reeds.

7. The retinal age-related disease treatment device for transdermal action on the upper eyelid according to claim 5, characterized by, Both ends of the power transmission line (4) are detachably connected with the jack (106) and the control assembly (3).

Images